Literature DB >> 25581609

The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.

Kohei Hashimoto1, Yuki Kyoda1, Toshiaki Tanaka1, Toshihiro Maeda1, Ko Kobayashi1, Kohsuke Uchida2, Hiroshi Kitamura1, Koichi Hirata3, Taiji Tsukamoto1, Naoya Masumori1.   

Abstract

Neuroendocrine (NE) cells in prostate cancer have been shown to be associated with the progression of prostate cancer. However, little is known about the molecular basis of this association. We have previously demonstrated that NE cells promote metastasis of a human prostate cancer cell line (LNCaP) with overexpression of the gelsolin gene. The purpose of this study was to investigate the interactions between NE cells and LNCaP cells and the involvement of gelsolin in contributing to the invasive potential of LNCaP cells. In addition, we examined whether neurotensin induced gelsolin-mediated invasion. We used the NE cell line NE-CS that was established from the prostate of the LPB-Tag 12T-10 transgenic mouse. Small interfering RNA (siRNA) targeting gelsolin or not targeting it was transfected into LNCaP cells. Cell invasion was assessed by Matrigel invasion assay. The supernatant of NE-CS cells and neurotensin induced the transformation of LNCaP cells. Neurotensin was observed in the supernatant of NE-CS cells but not in LNCaP cells. The siRNA targeting of gelsolin resulted in inhibition of invasion of LNCaP cells in the culture medium with neurotensin added, and in the supernatant of NE-CS cells with epidermal growth factor. The invasive potential of LNCaP cells enhanced by neurotensin or the supernatant of NE-CS cells through neurotensin receptor 1 (NTSR1) was blocked by a phospholipase Cγ inhibitor and an intracellular calcium chelator, with concomitant gelsolin suppression. This study indicates that NE cells and neurotensin induce gelsolin-mediated invasion of LNCaP cells through NTSR1 activation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25581609     DOI: 10.1038/labinvest.2014.165

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  50 in total

1.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.

Authors:  T Jiborn; A Bjartell; P A Abrahamsson
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

2.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.

Authors:  Xuezhen Yang; Min-Wei Chen; Stephane Terry; Francis Vacherot; Dominique K Chopin; Debra L Bemis; Jan Kitajewski; Mitchell C Benson; Yinglu Guo; Ralph Buttyan
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 4.  Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.

Authors:  Indranil Paul; Seemana Bhattacharya; Anirban Chatterjee; Mrinal K Ghosh
Journal:  Genes Cancer       Date:  2013-11

5.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.

Authors:  Anna V Lapuk; Chunxiao Wu; Alexander W Wyatt; Andrew McPherson; Brian J McConeghy; Sonal Brahmbhatt; Fan Mo; Amina Zoubeidi; Shawn Anderson; Robert H Bell; Anne Haegert; Robert Shukin; Yuzhuo Wang; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Yongjun Zhao; Marco A Marra; Andrea Fanjul; Christopher A Maher; Arul M Chinnaiyan; Mark A Rubin; Himisha Beltran; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-07       Impact factor: 7.996

Review 6.  Rho GTPases: signaling, migration, and invasion.

Authors:  A A Schmitz; E E Govek; B Böttner; L Van Aelst
Journal:  Exp Cell Res       Date:  2000-11-25       Impact factor: 3.905

7.  Loss of Gelsolin expression in human ovarian carcinomas.

Authors:  Aurelia Noske; Carsten Denkert; Hagen Schober; Christine Sers; Bakhyt Zhumabayeva; Wilko Weichert; Manfred Dietel; Kai Wiechen
Journal:  Eur J Cancer       Date:  2005-02       Impact factor: 9.162

8.  An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line.

Authors:  Naoya Masumori; Karen Tsuchiya; William H Tu; Charles Lee; Susan Kasper; Taiji Tsukamoto; Scott B Shappell; Robert J Matusik
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 10.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

View more
  7 in total

1.  DHA-mediated regulation of lung cancer cell migration is not directly associated with Gelsolin or Vimentin expression.

Authors:  Mehboob Ali; Kathryn Heyob; Lynette K Rogers
Journal:  Life Sci       Date:  2016-05-05       Impact factor: 5.037

2.  Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.

Authors:  Huaifu Deng; Hui Wang; Mengzhe Wang; Zibo Li; Zhanhong Wu
Journal:  Mol Pharm       Date:  2015-07-21       Impact factor: 4.939

3.  Capping Actin Protein Overexpression in Human Colorectal Carcinoma and Its Contributed Tumor Migration.

Authors:  Tsung-Jung Tsai; Yun-Ping Lim; Wen-Ying Chao; Chien-Chin Chen; Yi-Ju Chen; Ching-Yen Lin; Ying-Ray Lee
Journal:  Anal Cell Pathol (Amst)       Date:  2018-08-01       Impact factor: 2.916

4.  LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.

Authors:  Jie Luo; Keliang Wang; Shuyuan Yeh; Yin Sun; Liang Liang; Yao Xiao; Wanhai Xu; Yuanjie Niu; Liang Cheng; Sankar N Maity; Runze Jiang; Chawnshang Chang
Journal:  Nat Commun       Date:  2019-06-12       Impact factor: 14.919

5.  Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.

Authors:  Shimiao Zhu; Hao Tian; Xiaodan Niu; Jiang Wang; Xing Li; Ning Jiang; Simeng Wen; Xuanrong Chen; Shancheng Ren; Chuanliang Xu; Chawnshang Chang; Amilcar Flores-Morales; Zhiqun Shang; Yinghao Sun; Yuanjie Niu
Journal:  Oncogene       Date:  2019-02-15       Impact factor: 9.867

6.  Secreted gelsolin desensitizes and induces apoptosis of infiltrated lymphocytes in prostate cancer.

Authors:  Chun-Chi Chen; Shiow-Her Chiou; Cheng-Lin Yang; Kuan-Chih Chow; Tze-Yi Lin; Hui-Wen Chang; Weir-Chiang You; Hisu-Wen Huang; Chien-Min Chen; Nien-Cheng Chen; Fen-Pi Chou; Ming-Chih Chou
Journal:  Oncotarget       Date:  2017-08-23

7.  NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma.

Authors:  Yingnan Ye; Xinxin Long; Lijie Zhang; Jieying Chen; Pengpeng Liu; Hui Li; Feng Wei; Wenwen Yu; Xiubao Ren; Jinpu Yu
Journal:  Oncotarget       Date:  2016-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.